- Samsung (KS:) Biologics to supply ADC providers at new devoted facility
- Prolonged collaboration displays profitable partnership and experience
INCHEON,
Samsung Biologics will assist a sequence of LigaChem Biosciences’ ADC packages at Samsung Biologics’ new devoted ADC facility. The 2 firms have already been collaborating on ADC packages for the remedy of strong tumors. LigaChem Biosciences is a biotech pioneering analysis and improvement of ADC candidates.
“The latest collaboration will further strengthen Samsung Biologics’ capabilities across all stages of ADC development and manufacturing as part of our commitment to deliver safe and high-quality therapeutics to patients,” stated
“This collaboration with Samsung Biologics will be an important step toward strengthening the supply chain of high-quality ADC drugs and enhancing the competitiveness of both companies in the global ADC market,” stated
Samsung Biologics’ ADC facility is a segregated suite, outfitted with a 500-liter reactor, supporting the event and manufacture of ADC therapies. Constructing on the corporate’s observe file of experience in large-scale antibody manufacturing and course of engineering, Samsung Biologics’ ADC service scope spans late discovery to improvement and conjugation.
Samsung Biologics has additionally been making energetic investments via the Samsung Life (KS:) Science Fund in biotech firms pioneering ADC linker applied sciences, toolbox, and protein engineering.
For extra info, go to: https://samsungbiologics.com/providers/adc
About Samsung Biologics Co., Ltd.
Samsung Biologics (KRX: 207940.KS) is a completely built-in, end-to-end CDMO service supplier, providing seamless improvement and manufacturing options from cell line improvement to last aseptic fill/end in addition to laboratory testing assist for the biopharmaceutical merchandise we manufacture. Our state-of-the-art amenities are CGMP compliant with bioreactors starting from small to massive scales to serve various consumer wants. Maximizing operational effectivity and increasing our capabilities in response to rising biomanufacturing demand, Samsung Biologics affords a mixed 604 kL complete capability at Bio Campus I. The corporate launched Bio Campus II with the development of Plant 5, which will likely be operational in April 2025, including 180 kL biomanufacturing capability. Moreover, Samsung Biologics America permits the corporate to work in nearer proximity to purchasers primarily based within the
About LigaChem Biosciences
LigaChem Biosciences, Inc. (LCB) is a medical stage biopharmaceutical firm devoted to the invention and improvement of revolutionary medicines by leveraging the medicinal chemistry experience to make typical biologics extra focused and potent for the good thing about sufferers with illnesses of extremely unmet medical wants. LCB is advancing sustainable pipelines in therapeutic areas inside antibiotics, anti-fibrotics, oncology, and ADC platform expertise. For additional info, go to https://ligachembio.com/
Samsung Biologics Contact
[email protected]
LigaChem Biosciences Contact
[email protected]
